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124 Poster Session-IIMethods: 24 clinicians, (‘‘non-expert MD’’, n 5 16; ‘‘non-expert
non-MD’’; n5 4; and oral ‘‘expert’’, n5 4), from six major transplant
centers scored high-quality intraoral photographs of 12 patients.
The same photographs were evaluated 1 week later by the same eval-
uators. An intra-class correlation coefficient (ICC) was used to calcu-
late intra-rater reliability and inter-rater agreement was analyzed
using a weighted k statistic: 0 # k # 0.20 5 poor, 0.21 # k # 0.40
5 fair, 0.41 # k # 0.60 5 moderate, 0.61 # k # 0.80 5 good,
0.81 # k # 1.00 5 very good. Data on participant experiences and
demographics were also collected.
Results: Mean inter-rater reliability for each element was poor to
moderate (range 0.15 – 0.46). Overall mean kappa scores were high-
est for ULCERS (0.46), followed by ERYTHEMA (0.23) and lowest
for LICHENOID (0.15) and MUCOCELES (0.14). Kappa scores
were higher in ‘‘expert’’ compared with ‘‘non-expert MD’’ and
‘‘non-expert non-MD’’ in ULCERS and ERYTHEMA (e.g. 0.85,
0.44, 0.33 for ULCERS, respectively), but similar in LICHENOID
and MUCOCELES. Overall intra-rater reliability in all groups was
very good ($0.90) and highest for ULCERS (0.97, 0.85, 0.94).
While 75% of ‘‘experts’’ were comfortable with their abilities to score
the cases, approximately 50% of ‘‘non-experts’’ were uncomfortable.
The majority felt that their evaluations were accurate, however
84% agreed that formal training is required.
Conclusions: Inter-rater variability of the oral cGVHD instru-
ment is unacceptable for the purposes of clinical trials. Greater con-
cordance among ‘‘experts’’, high intra-rater reliability, and
participant feedback suggests that formal training may significantly
decrease variability. Parallel investigations must be completed using
the other organ specific instruments prior to any revision and wide-
spread prospective utilization of these tools as research endpoints.346
INTERACTIONS BETWEEN DC AND T-CELLS INITIATE COUNTER-REGU-
LATORY IMMUNE ACTIVITIES THAT LIMITS AMPLIFICATION OF ALLO-IM-
MUNE RESPONSES AND GvHD
Lu, Y., Li, J.-M., Harris, W., Waller, E. Winship Cancer Institute,
Emory University, Atlanta, GA
Acute graft-versus-host disease (GvHD) remains a major compli-
cation following allogenic hematopoietic stem cell transplant
(HSCT). Our reports and several publications have suggested a po-
tential beneficial effect of donor DC during HSCT. Using allogeneic
MHC-mismatched HSCT mice model, we previously demonstrated
that recipients transplanted with FACS-purified CD11b- DC with
HSC and T-cells had increased GvL and limited GvHD. In the cur-
rent study, we found that transplantation of T-cells from IFN-g
knock-out mice resulted in severe GvHD and higher levels of Th17
cells compared with recipients of T-cells from wide-type (WT)
mice, suggesting that donor T-cell synthesis of IFN-g induced by
donor DC is necessary to augment expansion of allo-reactive T-cells
that mediate GvL while subsequently limiting generalized activation
of donor T-cells that lead to off-target effects and GvHD. In order to
further clarify the mechanisms involved in the action of donor DC on
the limitation of GvHD, we detected the level of the IFN-g-induc-
ible indoleamine-2,3-dioxygenase(IDO) protein, which has been re-
ported to exert inhibitory effects on T cells activity, on donor DCs
and its potential roles in regulating donor T cell allo-immune activ-
ity. We set up an in vitro co-culture system including purified
CD11b- DC from WT or IDO knock-out mice and CFSE-labeled
syngeneic T cells in the presence of allogeneic antigen. T-cells co-
cultured with CD11b- DC had higher proliferation rates compared
with T-cells cultured with allo-antigen in the absence of DCs. Fur-
thermore, CD8 T-cells proliferated earlier and more than CD4
T-cells in response to alloantigen in the presence of CD11b- DC,
suggesting CD8 T-cells be mainly responsible for the observed
GvL activity in murine model systems. IDO expression on WT
CD11b- DC was increased in 3–7 day cultures containing syngeneic
T cells and allo-antigen but not on DC cultured with allo-antigen
alone. Thus, IFN-g-induced IDO expression on CD11b- donor
DCs might be a critical downstream event that inhibits continued
T-cell activation by initiating counter-regulatory immune activities
that limit allo-immune responses. Interestingly, T cells co-cultured
with CD11b1 DC from IDO knock-out donors had higher prolifera-tion rate than T cells co-cultured with CD11b- DC on day-7. Fur-
ther studies using IDO knock-out mice as DC donors in our
C57BL/6/B10.BR transplant model are essential to understand
the role of IDO expression of DC in allogeneic HSCT.347
INHIBITION OF GSK3 AND mTOR ENHANCES THE STEMNESS OF ACTI-
VATED CD81 T CELLS
Kato, K.1, Cui, S.1, Mineishi, S.1, Kuick, R.2, Huagh, J.3, Klein, P.3,
Reddy, P.1, Ferrara, J.1,2, Emerson, S.G.3,4, Zhang, Y.1 1University of
Michigan, Ann Arbor, MI; 2niversity of Michigan, Ann Arbor, MI;
3Univesrity of Pennsylvania, Philadelphia, PA; 4Haverford College, Phil-
adelphia, PA
Memory T cells have the ability to vigorously proliferate and to
generate differentiated effector cells upon reencounter of the cog-
nate antigen, while self-renewing. This stemness property of mem-
ory T cells has been explored for adoptive T cell immunotherapy.
On the other hand, it may be particularly difficult to treat memory
T cell-mediated inflammatory disorders, such as graft-versus-host
disease (GVHD) among others, unless long-lived memory T cells
are effectively targeted. However, the molecular mechanisms that
regulate the stemness of memory T cells remain unknown. Using
mouse GVHD models, we have previously identified a population
of alloreactive postmitotic CD44loCD62LhiCD81 memory T cells
(TPM) that induce GVHD. These TPM cells are able to generate
all subsets of effector and memory T cells and have greater ability
than both effector memory T cells (TEM) and central memory T cells
(TCM) to proliferate, while self-renewing. These data suggest that
TPM cells contain higher frequency of T memory stem cells than
other memory T cell subsets. In the present study, we found that
these TPM cells were initially generated during host antigen-priming
of donor T cells and persisted throughout the disease course. Gene
microarray analysis revealed that TPM cells represented the earliest
antigen-experienced CD81 T cells to become effector and memory
T cells, whereas TEM cells were terminally differentiated cells. As
comparison, TCM cells were the intermediates between TPM cells
and TEM cells. Interestingly, during differentiation of TPM cells to
TEM cells, Wnt-signaling activity was dramatically decreased,
whereas mTOR activity was augmented. A similar molecular profil-
ing of alloreactive T cells was also found in activated TCR-trans-
genic CD81 T cells specific to LCMV gp33 peptide. Inhibition of
either GSK3 or mTOR during antigenic-priming of CD81 T cells
significantly enhanced the generation of memory T cells specific to
gp33 peptide. Thus, both GSK3- and mTOR-mediated signals
play important roles in regulating the stemness of activated CD81
T cells. These findings have significant implications in the develop-
ment of new methods to treat ongoing GVHD and to augment adop-
tive T cell cancer therapy.348
OPTIMIZATION OF ALEMTUZUMAB DOSE FOR GRAFT-VERSUS-HOST DIS-
EASE PROPHYLAXIS FOR REDUCED INTENSITY TRANSPLANTATION
FROM UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC
MALIGNANCIES
Gupta, V.1, Xu, W.2, Sutherland, R.3, Kamel-Reid, S.3, Kuruvilla, J.1,
Loach, D.1, Lipton, J.H.1, Messner, H.A.1 1Princess Margaret Hospital,
Toronto, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Can-
ada; 3University Health Network, Toronto, ON, Canada
It has been shown that a high dose of alemtuzumab (100mg) in
combination with cyclosporine (CsA) significantly reduces the risk
of acute and chronic GVHD, however a high risk of relapse compro-
mises the transplant outcomes. We hypothesized that a lower dose of
alemtuzumab for GVHD prophylaxis may help in achieving a bal-
ance between prevention of severe GVHD while preserving
a Graft-versus-leukemia (GVL) effect. We studied the use of a lower
dose of alemtuzumab with CsA as GVHD prophylaxis in 36 patients
undergoing reduced intensity conditioning (RIC) using matched un-
related donors. The study includes two sequential cohorts treated at
Princess Margaret Hospital between September 2004 and July 2007:
cohort 1 (n 5 17) received 60 mg of IV alemtuzumab (10mg, 20mg
and 30 mg on days –8,27 and –6); cohort 2 (n5 19) received 30 mg
Poster Session-II 125alemtuzumab (a single subcutaneous dose on day –6). CsA was ta-
pered off on day 56 in the absence of GVHD. RIC protocol consisted
of fludarabine (30 mg/m2 x 4 days on days -5 to -2) and IV Busulphan
(3.2 mg/KBW x 2 days on days -3 and -2) with or without 200cGY of
TBI. Median follow-up of survivors was 24 months (range 15–48).
The median age at transplant was 52 years (range 33–64) and 15
pts. (42%) had significant co-morbidities (score of $3 using
HCT-specific index). 34 pts.(94%) had high-risk malignancies.
The source of hematopoietic cells was: peripheral blood, 31; and
bone marrow, 5. The cumulative incidence of relapse, non-relapse
mortality (NRM), progression-free and overall survivals at 1-year
were 19% (95% CI 10–38), 28% (95% CI 16–48), 53% (95% CI
35–67) and 61%(95% CI 43–75), respectively and no significant dif-
ferences were observed in two cohorts. The major cause of NRM was
infectious complications. Lymphocyte recovery at 30, 60 and 90 days
was significantly faster in the cohort 2, no differences were noted at
later time points (6, 9 and 12 months). The data on hematopoietic
recovery, engraftment and GVHD related parameters are summa-
rized in table 1.
Table 1: Hematopoietic recovery, engraftment, acute and
chronic GVHD in patients undergoing unrelated trans-
plantation using alemtuzumab based GVHD prophylaxis
Cohort 1 - Cohort 2 - P valueCharacteristics pWhole study
atients (n536)
a
6lemtuzumab
0mg(n517)
a
3lemtuzumab
0 mg (n519)
(cohort 1 vs.
cohort 2)Median days to
neutrophil recovery
(range)19 (12–29) 20 (15–29) 16 (12–22) 0.001Median days to platelet
recovery(range)13 (9–33) 14 (10–33) 11 (9–24) 0.10Median % donor cells
on day 30 (range)98 (52–100) 98 (52–100) 99 (76–100) 0.89Median % donor cells on
day 60 (range)98 (8–100) 99 (8–100) 98 (87–100) 0.14Median % donor cells
on day 120 (range)98 (5–100) 96 (5–100) 98 (73–100) 0.39Graft failure (Primary/
Late)2/2 1/1 1/1 1.00Median days to onset
of acute GVHD (range)40 (9–168) 46 (9–89) 38 (15–168) 1.00Cumulative incidence
of $ grade 2 acute
GVHD (95% CI)
@ 200 days
58% (44–77) 59% (39–90) 58 (39–87) 0.98Median days to onset
of chronic GVHD (range)
153 (101–541) 144 (101–369) 174 (102–541) 0.67Cumulative incidence of
chronic GVHD
(95% CI) @ 1-year
42% (28–64) 38% (19–72) 47% (28–80) 0.56Of note, no cases of grade 4 acute GVHD, steroid refractory acute
GVHD or severe chronic GVHD (using NIH consensus criteria on
global severity of chronic GVHD) in any of the cohorts. Our data
suggest that a low dose of alemtuzumab (30 mg) with CsA is an effec-
tive GVHD prophylaxis for the prevention of severe acute and
chronic GVHD with acceptable risk of relapse in the setting of
RIC for MUD transplantation and warrants further studies.349
AMENDING NIH CONSENSUS CRITERIA FOR THE CLINICAL DIAGNOSIS OF
BRONCHIOLITIS OBLITERANS AFTER HSCT
Williams, K.M.1, Gladwin, M.T.2, Chien, J.W.3, Louie, A.4, Baird, K.5,
Shelhamer, J.H.6, Blacklock-Schuver, B.A.J.1, Avila, D.1, Mitchell, S.7,
Krumlauf, M.1, Gress, R.E.1, Pavletic, S.Z.1 1NIH/NCI, Bethesda,
MD; 2University of PittsburghMedical Center, Pittsburgh, PA; 3Univer-
sity of Washington, Seattle, WA; 4National Institutes of Health, Bethesda,
MD; 5NIH/NCI, Besthesda, MD; 6CC/NIH, Bethesda, MD; 7NIH, Be-
thesda, MD
Bronchiolitis obliterans (BO) after HSCT is a rare and morbid
manifestation of cGVHD. Although lung biopsy is the gold standardfor diagnosis, the high complication rate restricts its use. There is
a lack of consensus in the literature concerning the diagnostic criteria
using non-invasive modalities. Thus, the NIH cGVHD consensus
project developed a definition for BO after HSCT based on clinical
characteristics of BO after lung transplant. This definition required
for non-pathologic diagnosis: a) Absence of infection, b) presence of
another cGVHD sign, c) FEV-1\75% and d) all 3 parameters to
confirm obstruction: 1) FEV1/FVC\0.7, 2) RV. 120%, and 3)
CT findings (table). To explore the sensitivity of these criteria, we
evaluated this definition in a group of patients with diagnoses of
cGVHD and BO (corroborated by NIH pulmonologists). Twenty-
four patients were identified; 1 was excluded for relapse and 1 for
lack of full PFTs. We then analyzed pulmonary and radiographic pa-
rameters of these 15 clinically identified cases of BO and 7 biopsy
proven cases. Only 18% (4/22) of patients met the NIH consensus
definition for a clinical diagnosis of BO, all of which had an
FEV1\ 55% suggestive of severe disease. While the majority of
the total had FEV1/FVC\0.7, using the slow vital capacity
(FEV1/SVC) enhanced sensitivity, capturing patients with airways
that collapse early, artificially lowering the FVC.
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Criteria86% 100%We then evaluated the patients that did not meet the new ratio cri-
teria (FEV1/SVC\0.7); all (6/6) had evidence of severe restriction
from scleroderma or myositis, thus masking the ratio evidence of ob-
struction. Because of their restrictive disease, the total lung capacity
(TLC) was decreased, also artificially lowering the RV. When RV/
TLC.120% of predicted was used with RV.120% predicted, 5/6
of these could be captured as BO and all had air trapping confirmed
on expiratory CT. Therefore, we amended the definition of BO to
confirm obstruction by either: 1) FEV1/SVC\0.7 OR air trapping
on CT with RV or RV/TLC . 120%. Using this amended defini-
tion, all but 1 case (biopsy proven) of our cohort could be captured
clinically, increasing our sensitivity from 18% to 95%. We therefore
present a modification of the NIH consortium criteria that our data
suggests enhances the sensitivity of this test in our cGVHD popula-
tion. These criteria will require further validation for integration
into future trials.
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ACUTE GRAFT VERSUS HOST DISEASE (GVHD) FOLLOWING REDUCED IN-
TENSITY (RIC) TRANSPLANTS USING SIBLING DONORS: INCIDENCE,
OUTCOME AND ANALYSIS OF RISK FACTORS
George, B., Kerridge, I., McGurgan, M., Huang, G., Gottlieb, D.,
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